Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Asciminib
Drug ID BADD_D02528
Description Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.[L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1. Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those that target the inactive kinase domain ([imatinib], [nilotinib], [ponatinib]).[A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation.[L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000]
Indications and Usage Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with ≥2 tyrosine kinase inhibitors.[L38995] It is also indicated in the treatment of Ph+ CML in adult patients with the T315I mutation.[L38995]
Marketing Status approved; investigational
ATC Code L01EA06
DrugBank ID DB12597
KEGG ID D11403
MeSH ID C000621806
PubChem ID 72165228
TTD Drug ID DSHT18
NDC Product Code 0078-1091; 0078-1098
UNII L1F3R18W77
Synonyms asciminib | ABL001 | asciminib hydrochloride
Chemical Information
Molecular Formula C20H18ClF2N5O3
CAS Registry Number 1492952-76-7
SMILES C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema08.01.07.006; 14.05.06.0100.000381%-
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.0110.000112%
Pain in extremity15.03.04.0100.000492%
Pancreatitis07.18.01.0010.000224%
Pancytopenia01.03.03.0030.000616%-
Pericardial effusion02.06.01.0020.000112%
Pericarditis02.06.02.0010.000112%
Pleural effusion22.05.02.0020.000280%
Renal failure20.01.03.0050.000112%-
Respiratory failure14.01.04.003; 22.02.06.0020.000112%
Seizure17.12.03.0010.000168%
Thrombocytopenia01.08.01.0020.000616%-
Vision blurred06.02.06.007; 17.17.01.0100.000246%
Vomiting07.01.07.0030.000280%
Cardiotoxicity02.11.01.009; 12.03.01.0070.000112%-
Malignant neoplasm progression16.16.01.0050.000392%-
Acute coronary syndrome02.02.02.015; 24.04.04.0110.000112%-
Decreased appetite08.01.09.028; 14.03.01.0050.000302%
Disease progression08.01.03.0380.000112%
Drug intolerance08.06.01.0130.000246%-
Renal impairment20.01.03.0100.000280%-
Cytopenia01.03.03.0120.000560%-
Concomitant disease aggravated08.01.03.0630.000224%-
Acute lymphocytic leukaemia recurrent01.10.01.003; 16.01.01.0030.000224%-
Illness08.01.03.0910.000302%-
Myelosuppression01.03.03.0150.000112%-
Therapeutic product effect incomplete08.06.01.0520.000246%-
The 2th Page    First    Pre   2    Total 2 Pages